Fig. 2.

CU06-1004 inhibits astrocyte end-feet swelling and activation after I/R

a Comparisons of astrocyte changes among the sham, vehicle-I/R, and CU06–1004-I/R groups. Square, enlarged image of the region. Tissues were immunostained for GFAP, as an astrocyte marker, and CD31, as an EC marker. b Quantification of astrocyte end-feet diameter and c GFAP expression levels. n = 5 per group. **P < 0.01 and ***P < 0.001. Scale bars, 20 μm. Error bars indicate mean ± SEM. ns, not significant; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; CD31, cluster of differentiation 31; 1004, CU06-1004